Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 1000394 in MCL1/MYC/CCNE1-amplified solid tumors
NCT02656849Phase 2Withdrawn
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2016
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of roniciclib in solid tumor, sponsored by Dana-Farber Cancer Institute. Planned start Feb 2016; status: withdrawn.
02
Drugs
roniciclib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02656849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02656849.